- Home
- Publications
- Publication Search
- Publication Details
Title
Disease-modifying strategies for Parkinson's disease
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume 30, Issue 11, Pages 1442-1450
Publisher
Wiley
Online
2015-07-24
DOI
10.1002/mds.26354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system
- (2015) Katrina L. Paumier et al. EXPERIMENTAL NEUROLOGY
- Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease
- (2015) Karl Kieburtz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model
- (2014) Shih-Chun Ho et al. BEHAVIOURAL BRAIN RESEARCH
- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)
- (2014) Raghava R Kethiri et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
- (2014) J. Schapansky et al. HUMAN MOLECULAR GENETICS
- Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice
- (2014) J. Mark Cooper et al. MOVEMENT DISORDERS
- Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic
- (2014) Andrew B. West MOVEMENT DISORDERS
- Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
- (2014) Mike A Nalls et al. NATURE GENETICS
- Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation
- (2014) Xuelai Fan et al. NATURE NEUROSCIENCE
- Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
- (2014) Veronica Lindström et al. NEUROBIOLOGY OF DISEASE
- Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
- (2014) B. Ritz et al. NEUROLOGY
- Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation
- (2014) Luis Fonseca-Ornelas et al. Nature Communications
- α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
- (2014) Hien T. Tran et al. Cell Reports
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
- (2014) Michael A. Schwarzschild et al. JAMA Neurology
- A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
- (2014) et al. JAMA Neurology
- Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
- (2013) Paolo Ruzza et al. ACS Chemical Neuroscience
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
- (2013) Jens Wagner et al. ACTA NEUROPATHOLOGICA
- Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
- (2013) Ariadna Recasens et al. ANNALS OF NEUROLOGY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
- (2013) Anthony HV Schapira et al. LANCET NEUROLOGY
- Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model
- (2013) Tanya Chotibut et al. MOLECULAR NEUROBIOLOGY
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Lysosomal impairment in Parkinson's disease
- (2013) Benjamin Dehay et al. MOVEMENT DISORDERS
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
- (2013) R. T. Bartus et al. NEUROLOGY
- Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
- (2013) Amaal AlDakheel et al. Neurotherapeutics
- TFEB-mediated autophagy rescues midbrain dopamine neurons from -synuclein toxicity
- (2013) M. Decressac et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The prion hypothesis in Parkinson's disease: Braak to the future
- (2013) Naomi P Visanji et al. Acta Neuropathologica Communications
- Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein
- (2013) Amanda N Sacino et al. Acta Neuropathologica Communications
- Meta-analysis of early nonmotor features and risk factors for Parkinson disease
- (2012) Alastair J. Noyce et al. ANNALS OF NEUROLOGY
- α-Synuclein oligomers and clinical implications for Parkinson disease
- (2012) Lorraine V. Kalia et al. ANNALS OF NEUROLOGY
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Urate in Parkinson’s Disease: More Than a Biomarker?
- (2012) Xiqun Chen et al. Current Neurology and Neuroscience Reports
- Calcium, Bioenergetics, and Neuronal Vulnerability in Parkinson's Disease
- (2012) D. James Surmeier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
- (2012) Kelvin C. Luk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway
- (2012) Li Gong et al. JOURNAL OF NEUROCHEMISTRY
- Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans
- (2012) Gusheng Wu et al. JOURNAL OF NEUROSCIENCE RESEARCH
- A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients
- (2012) Jay S. Schneider et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain
- (2012) J W Steele et al. MOLECULAR PSYCHIATRY
- Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease
- (2012) Katrina L. Paumier et al. MOVEMENT DISORDERS
- Caffeine for treatment of Parkinson disease: A randomized controlled trial
- (2012) R. B. Postuma et al. NEUROLOGY
- Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
- (2012) X. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- (2011) E. Ilijic et al. NEUROBIOLOGY OF DISEASE
- Mice Lacking Major Brain Gangliosides Develop Parkinsonism
- (2011) Gusheng Wu et al. NEUROCHEMICAL RESEARCH
- Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers
- (2011) C. Marras et al. NEUROLOGY
- Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases
- (2010) Maurizio Renna et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains
- (2010) Raymond T. Bartus et al. MOVEMENT DISORDERS
- Glutathione—a review on its role and significance in Parkinson’s disease
- (2009) Heather L. Martin et al. FASEB JOURNAL
- Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response
- (2008) Mahmoud M. Iravani et al. EXPERIMENTAL NEUROLOGY
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
- (2008) William J Marks et al. LANCET NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started